Who is affected by this change?

This affects Independence Blue Cross Oncology, Hematology providers on Medicare Advantage plans.

When does this change take effect?

This change is effective Apr 2, 2025.

Back to dashboard

Medicare AdvantageCoverageMedium impact

MA08.168, Elranatamab-bcmm (Elrexfio™)

Independence Blue Cross·Oncology, Hematology·Pharmacy

Effective date

Apr 2, 2025

We identified it

Jun 19, 2026

Days to comply

—

Summary

Medicare Advantage policy MA08.168 for Elranatamab-bcmm (Elrexfio™) has been reissued and will take effect April 2, 2025. This pharmacy policy update may affect coverage criteria, prior authorization requirements, or billing procedures for this oncology medication.

Action Required

Action needed

By April 2, 2025: Review the complete policy details at the provided URL to understand specific changes to Elranatamab-bcmm (Elrexfio™) coverage requirements. Update prior authorization workflows and billing procedures as specified in the full policy. Notify oncology providers of any new coverage criteria or documentation requirements.

Related policy hubs

Independence Blue Cross policies Oncology Hematology